MX2018008903A - COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. - Google Patents
COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.Info
- Publication number
- MX2018008903A MX2018008903A MX2018008903A MX2018008903A MX2018008903A MX 2018008903 A MX2018008903 A MX 2018008903A MX 2018008903 A MX2018008903 A MX 2018008903A MX 2018008903 A MX2018008903 A MX 2018008903A MX 2018008903 A MX2018008903 A MX 2018008903A
- Authority
- MX
- Mexico
- Prior art keywords
- hmb
- lipophagy
- methods
- methylbutyrate
- hydroxy
- Prior art date
Links
- 230000004900 autophagic degradation Effects 0.000 title abstract 3
- 230000004918 lipophagy Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 title 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona una composición que comprende HMB. También se describen métodos para administrar HMB a un animal. El HMB se administra para modular la autofagia y lipofagia. El HMB también se administra para tratar, prevenir, inhibir, retardar o reducir condiciones o enfermedades mediadas por autofagia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662281561P | 2016-01-21 | 2016-01-21 | |
| PCT/US2017/014328 WO2017127675A1 (en) | 2016-01-21 | 2017-01-20 | COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018008903A true MX2018008903A (es) | 2019-02-21 |
Family
ID=59360054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018008903A MX2018008903A (es) | 2016-01-21 | 2017-01-20 | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10213399B2 (es) |
| EP (2) | EP4049723A1 (es) |
| JP (3) | JP2019506393A (es) |
| CN (1) | CN109641135A (es) |
| AU (3) | AU2017210335A1 (es) |
| BR (2) | BR122023026038A2 (es) |
| CA (1) | CA3011981C (es) |
| MX (1) | MX2018008903A (es) |
| WO (1) | WO2017127675A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11406609B2 (en) * | 2016-01-21 | 2022-08-09 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy |
| WO2018012769A1 (ko) * | 2016-07-12 | 2018-01-18 | 연세대학교 산학협력단 | 자가포식 향상물질 및 그 용도 |
| CN109549953A (zh) * | 2017-09-27 | 2019-04-02 | 中国科学技术大学 | 调控tfeb以减弱保护性自噬促进纳米银抗肿瘤治疗的方法 |
| EP3986557A1 (en) * | 2019-06-20 | 2022-04-27 | Société des Produits Nestlé S.A. | Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids |
| CN110724203B (zh) * | 2019-11-08 | 2021-04-30 | 中国人民解放军第四军医大学 | 一种促进tfeb核转位的短肽及基于其的线性短肽和其减轻脑缺血损伤的应用 |
| CN111227243A (zh) * | 2020-02-28 | 2020-06-05 | 昆明医科大学第一附属医院 | 一种具有特殊医学用途配方的食品 |
| CA3182874A1 (en) * | 2020-06-15 | 2021-12-23 | Karina BETTEGA FELIPE | Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) and chemotherapy agents |
| CN116459343A (zh) * | 2023-04-19 | 2023-07-21 | 南方科技大学 | 抑制脂肪细胞中Kindlin-2蛋白表达的试剂在制备治疗关节炎产品中的应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028440A (en) | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| US4992470A (en) | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
| DE69327468T2 (de) | 1992-09-16 | 2000-05-11 | Iowa State University Research Foundation, Inc. | Verfahren zur reduktion der blutspiegel von gesamtcholesterin und ldl-cholesterin |
| US5348979A (en) | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
| US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| US20050215640A1 (en) * | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| ES2608483T3 (es) | 2009-12-18 | 2017-04-11 | Metabolic Technologies, Inc. | Método mejorado de administración de beta-hidroxi-beta-metilbutirato (HMB) |
| RU2017129378A (ru) * | 2011-07-15 | 2019-02-04 | Нусерт Сайенсиз, Инк. | Композиции и способы модулирования метаболических путей |
| EP2647374A1 (en) | 2012-04-04 | 2013-10-09 | Abbott Laboratories, Inc. | Nutritional compositions including beta-hydroxy-beta-methylbutyrate for regulating transcription factors |
| WO2013170189A1 (en) * | 2012-05-11 | 2013-11-14 | Abbott Laboratories | Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow |
| CN105188695A (zh) * | 2013-03-14 | 2015-12-23 | 雅培制药有限公司 | 与长期体力活动不足有关的胰岛素抗性的治疗 |
| US20150057346A1 (en) * | 2013-08-23 | 2015-02-26 | Abbott Laboratories | Methods of maintaining intramuscular myoglobin levels, maintaining maximal aerobic capacity, and enhancing the oxidative capacity of muscle in a subject |
| EP3052133A2 (en) | 2013-10-03 | 2016-08-10 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for modulating autophagy in a subject in need thereof |
| WO2015148982A1 (en) * | 2014-03-27 | 2015-10-01 | Winterfield Roland W | Beta-hydroxy beta-methylbutyrate for alleviating statin myopathy |
| US20160346238A1 (en) * | 2015-06-01 | 2016-12-01 | Metabolic Technologies, Inc. | Compositions and Methods of Use of -hydroxy--methylbutyrate (HMB) for Decreasing Fat Mass |
-
2017
- 2017-01-20 CN CN201780017407.7A patent/CN109641135A/zh active Pending
- 2017-01-20 EP EP22155278.9A patent/EP4049723A1/en active Pending
- 2017-01-20 MX MX2018008903A patent/MX2018008903A/es unknown
- 2017-01-20 EP EP17742008.0A patent/EP3405262A4/en not_active Withdrawn
- 2017-01-20 WO PCT/US2017/014328 patent/WO2017127675A1/en not_active Ceased
- 2017-01-20 CA CA3011981A patent/CA3011981C/en active Active
- 2017-01-20 BR BR122023026038-4A patent/BR122023026038A2/pt not_active Application Discontinuation
- 2017-01-20 US US15/411,303 patent/US10213399B2/en active Active
- 2017-01-20 AU AU2017210335A patent/AU2017210335A1/en not_active Abandoned
- 2017-01-20 BR BR112018014920A patent/BR112018014920A2/pt not_active Application Discontinuation
- 2017-01-20 JP JP2018538083A patent/JP2019506393A/ja active Pending
-
2022
- 2022-04-01 JP JP2022061623A patent/JP2022088611A/ja active Pending
- 2022-10-05 AU AU2022246406A patent/AU2022246406A1/en not_active Abandoned
-
2023
- 2023-10-24 JP JP2023182551A patent/JP2024010082A/ja active Pending
-
2024
- 2024-11-21 AU AU2024266783A patent/AU2024266783A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN109641135A (zh) | 2019-04-16 |
| JP2019506393A (ja) | 2019-03-07 |
| US20170209397A1 (en) | 2017-07-27 |
| CA3011981C (en) | 2024-01-16 |
| EP3405262A4 (en) | 2019-08-28 |
| EP3405262A1 (en) | 2018-11-28 |
| JP2024010082A (ja) | 2024-01-23 |
| CA3011981A1 (en) | 2017-07-27 |
| JP2022088611A (ja) | 2022-06-14 |
| AU2022246406A1 (en) | 2022-11-03 |
| BR122023026038A2 (pt) | 2024-01-16 |
| AU2017210335A1 (en) | 2018-08-02 |
| AU2024266783A1 (en) | 2024-12-12 |
| EP4049723A1 (en) | 2022-08-31 |
| US10213399B2 (en) | 2019-02-26 |
| BR112018014920A2 (pt) | 2018-12-18 |
| WO2017127675A1 (en) | 2017-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018008903A (es) | COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA. | |
| PH12019550050A1 (en) | Isoxazole analogs as fxr agonists and methods of use thereof | |
| PH12020552060A1 (en) | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | |
| EA201990665A1 (ru) | Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA201790992A1 (ru) | Иммунорегуляторные агенты | |
| PH12019502201A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12019502577A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| PH12015502028A1 (en) | Ido inhibitors | |
| PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
| EP4635568A3 (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX2016000295A (es) | Inhibidores de indoleamina 2,3-dioxigenasa (ido). | |
| PH12019502095A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
| PH12018502077A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| EP4338804A3 (en) | Epinephrine spray formulations | |
| PH12019502559A1 (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
| NZ757081A (en) | Somatostatin modulators and uses thereof | |
| MX2018011788A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue. | |
| EA201891377A1 (ru) | ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ | |
| TW201613578A (en) | Pharmaceutical combinations | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| PH12022551052A1 (en) | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |